

Alexander T Sandhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8716575/publications.pdf>

Version: 2024-02-01

40
papers

876
citations

623734

14
h-index

501196

28
g-index

40
all docs

40
docs citations

40
times ranked

1067
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Knee Arthroplasty Episode-Based Cost Measure for Evaluating Cost in the Merit-Based Incentive Payment System. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 70-77.	3.0	3
2	Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 130.	6.1	19
3	Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, e007993.	2.2	1
4	Assessment of coding-based frailty algorithms for long-term outcome prediction among older people in community settings: a cohort study from the Shizuoka Kokuho Database. <i>Age and Ageing</i> , 2022, 51, .	1.6	13
5	Economic Issues in Heart Failure in the United States. <i>Journal of Cardiac Failure</i> , 2022, 28, 453-466.	1.7	40
6	Variability in Coronary Artery Disease Testing for Patients With New-Onset Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 849-860.	2.8	15
7	Development of the Elective Outpatient Percutaneous Coronary Intervention Episode-Based Cost Measure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006461.	2.2	4
8	The Affordability of Guideline-Directed Medical Therapy. <i>Circulation</i> , 2021, 143, 1073-1075.	1.6	17
9	Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 388-396.	4.0	13
10	Correspondence to European Heart Journal – Quality of Care and Clinical Outcomes in response to letter by Dalal H. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, e8-e8.	4.0	0
11	Development of Episode-Based Cost Measures for the US Medicare Merit-based Incentive Payment System. <i>JAMA Health Forum</i> , 2021, 2, e210451.	2.2	3
12	Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. <i>JAMA Network Open</i> , 2021, 4, e2113969.	5.9	2
13	Automated coronary calcium scoring using deep learning with multicenter external validation. <i>Npj Digital Medicine</i> , 2021, 4, 88.	10.9	59
14	High-Deductible Health Plans and Emergency Care for Chest Pain: To Go or Not to Go. <i>Circulation</i> , 2021, 144, 350-352.	1.6	2
15	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 926.	6.1	65
16	Disparity in the Setting of Incident Heart Failure Diagnosis. <i>Circulation: Heart Failure</i> , 2021, 14, e008538.	3.9	28
17	Evidence – Practice Gap for Preventing Procedure-Related Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e020047.	3.7	3
18	Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant. <i>Journal of Heart and Lung Transplantation</i> , 2021, , .	0.6	8

#	ARTICLE	IF	CITATIONS
19	Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system. <i>American Heart Journal</i> , 2021, 240, 46-57.	2.7	4
20	Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries. <i>Vaccine</i> , 2021, . .	3.8	1
21	Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, CIRCOUTCOMES120007559.	2.2	1
22	Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2379-2390.	2.8	224
23	Adjustment For Social Risk Factors Does Not Meaningfully Affect Performance On Medicare's MIPS Clinician Cost Measures. <i>Health Affairs</i> , 2020, 39, 1495-1503.	5.2	6
24	Trends in Readmission and Mortality Rates Following Heart Failure Hospitalization in the Veterans Affairs Health Care System From 2007 to 2017. <i>JAMA Cardiology</i> , 2020, 5, 1042.	6.1	26
25	Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. <i>JAMA Network Open</i> , 2020, 3, e202004.	5.9	18
26	Association of Diagnostic Coding-Based Frailty and Outcomes in Patients With Heart Failure: A Report From the Veterans Affairs Health System. <i>Journal of the American Heart Association</i> , 2020, 9, e016502.	3.7	12
27	Association Between Neighborhood Social Risk and Hospital Readmission Reduction Penalties Under the New Stratified Approach. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006353.	2.2	1
28	Optimizing the Use of Heart Transplant in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1772.	7.4	3
29	Association Between Current and Future Annual Hospital Percutaneous Coronary Intervention Mortality Rates. <i>JAMA Cardiology</i> , 2019, 4, 1077.	6.1	5
30	Comparison of the change in heart failure readmission and mortality rates between hospitals subject to hospital readmission reduction program penalties and critical access hospitals. <i>American Heart Journal</i> , 2019, 209, 63-67.	2.7	8
31	Heart failure management with ambulatory pulmonary artery pressure monitoring. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 212-219.	4.9	8
32	Association Between Offering Limited Left Ventricular Ejection Fraction Echocardiograms and Overall Use of Echocardiography. <i>JAMA Internal Medicine</i> , 2018, 178, 1270.	5.1	10
33	Cardiovascular Testing and Clinical Outcomes in Emergency Department Patients With Chest Pain. <i>JAMA Internal Medicine</i> , 2017, 177, 1175.	5.1	62
34	Using Commercial Programs for Lifestyle Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 328-330.	2.8	2
35	Determinants of Hypertension in Urban Uganda: A Community-Based Case-Control Study. <i>Ethnicity and Disease</i> , 2017, 27, 15.	2.3	10
36	CardioMEMS HF for the Management of Heart Failure: Effectiveness and Value. <i>JAMA Internal Medicine</i> , 2016, 176, 1551.	5.1	16

#	ARTICLE	IF	CITATIONS
37	Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2016, 165, 681.	3.9	63
38	Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 368-375.	4.1	74
39	Sacubitril-Valsartan for the Treatment of Heart Failure. <i>JAMA Internal Medicine</i> , 2016, 176, 249.	5.1	26
40	Abstract 19839: Clinical and Economic Burden of Rheumatic Heart Disease in Low-Income Nations: Estimating the Cost-of-Illness in India and Uganda. <i>Circulation</i> , 2014, 130, .	1.6	1